[8-K] Armstrong World Industries, Inc. Reports Material Event

Rhea-AI Filing Summary

Serina Therapeutics, Inc. (NYSE American: SER) filed a Form 8-K on 29-Jul-2025 under Item 7.01 (Regulation FD). The filing furnishes—rather than files—a press release and an investor presentation (Exhibits 99.2 and 99.1) that spotlight the advancement of SER-270 (POZ-VMAT2i), a proprietary POZ-conjugated VMAT2 inhibitor in development for tardive dyskinesia. CEO Steve Ledger will discuss the program during the BTIG Virtual Biotechnology Conference on the same day using the accompanying presentation materials. No financial results, clinical data, guidance, or other material transactions are disclosed, and the company expressly states the furnished information will not be incorporated into future Securities Act filings unless specifically referenced. No other Items were reported.

Positive

• Pipeline visibility: Management spotlights SER-270, reinforcing pipeline momentum ahead of investor meetings.

Negative

• No new clinical or financial data: Filing offers no efficacy, safety, or revenue guidance, limiting immediate valuation impact.
• Information only furnished: Data are not deemed filed, suggesting limited materiality.

Insights

Biotech Equity Analyst

TL;DR: Neutral 8-K furnishes pipeline update; informative but lacks data or financial impact.

The company’s decision to highlight SER-270 via Regulation FD suggests it wants to raise visibility ahead of a conference rather than announce inflection-point results. Investors learn that a VMAT2 inhibitor has progressed internally, but without efficacy, safety, or regulatory milestones the disclosure is not immediately price-moving. The lack of financial metrics or guidance further limits impact. Nevertheless, the mention of proprietary POZ chemistry may remind the market of Serina’s platform potential and help management gauge investor interest.

0000007431false00000074312025-07-292025-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2025

ARMSTRONG WORLD INDUSTRIES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania		1-2116		23-0366390
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(IRS Employer Identification No.)
2500 Columbia Avenue P.O. Box 3001 Lancaster, Pennsylvania				17603
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (717) 397-0611

NA

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		AWI		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition.

On July 29, 2025, Armstrong World Industries, Inc. (the "Company") issued a press release announcing its second quarter 2025 consolidated financial results. The full text of the press release is attached hereto as Exhibit 99.1.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Section 7 – Regulation FD

Item 7.01 Regulation FD Disclosure.

On July 29, 2025, the Company issued a press release announcing that it will report its second quarter 2025 consolidated financial results via a webcast and conference call on July 29, 2025 at 10:00 a.m. Eastern Time which can be accessed through the “Investors” section of the Company’s website, www.armstrongceilings.com. During this report, the Company will reference a slide presentation, a copy of which is attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

No. 99.1		Press Release of Armstrong World Industries, Inc. dated July 29, 2025
No. 99.2		Earnings Call Presentation Second Quarter 2025 dated July 29, 2025
No. 104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARMSTRONG WORLD INDUSTRIES, INC.
By:		/s/ Austin K. So
		Austin K. So
		SVP General Counsel, Head of Government Relations & Chief Sustainability Officer

Date: July 29, 2025

3

FAQ

What event triggered Serina Therapeutics' July 29 2025 Form 8-K?

The company furnished a press release and presentation on the advancement of SER-270 and its appearance at the BTIG Virtual Biotechnology Conference.

Which SEC item was used in the Serina Therapeutics 8-K?

Item 7.01 – Regulation FD Disclosure.

What is SER-270 mentioned by Serina Therapeutics (SER)?

SER-270 is a POZ-conjugated VMAT2 inhibitor being developed for tardive dyskinesia.

Did the 8-K include financial results or guidance?

No. The filing contained no financial metrics, earnings data, or guidance.

Where can investors find the presentation materials?

The investor presentation is furnished as Exhibit 99.1 to the Form 8-K.

Is the furnished information considered filed for legal purposes?

No. Serina stated the information is furnished, not filed, and will not be incorporated into future filings unless specifically referenced.